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Abstract
This review provides an overview on the clinical management of chronic mesenteric ischemia (CMI). CMI is defined as
insufficient blood supply to the gastrointestinal tract, most often caused by atherosclerotic stenosis of one or more mes-
enteric arteries. Patients classically present with postprandial abdominal pain and weight loss. However, patients may
present with, atypically, symptoms such as abdominal discomfort, nausea, vomiting, diarrhea or constipation. Early con-
sideration and diagnosis of CMI is important to timely treat, to improve quality of life and to prevent acute-on-chronic
mesenteric ischemia. The diagnosis of CMI is based on the triad of clinical symptoms, radiological evaluation of the
mesenteric vasculature and if available, functional assessment of mucosal ischemia. Multidisciplinary consensus on the
diagnosis of CMI is of paramount importance to adequately select patients for treatment. Patients with a consensus diag-
nosis of single-vessel or multi-vessel atherosclerotic CMI are preferably treated with endovascular revascularization.
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Introduction
Chronic mesenteric ischemia (CMI) requires timely
diagnosis and treatment to prevent the development
of acute mesenteric ischemia, which is associated with
high morbidity and mortality. CMI is a diagnosis that
is diﬃcult to establish as symptoms are highly variable
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and diagnostic tests may be inconclusive. Recently,
three guidelines for CMI management have been pub-
lished: a clinical practice guideline of the European
Society of Vascular Surgery (ESVS),1 criteria on radio-
logical management by the American College of
Radiology (ACR)2 and quality improvement guidelines
for endovascular revascularization by the Society of
Interventional Radiology (SIR).3 Gastroenterology
guidelines on CMI are lacking. This review provides
an overview of available literature on the clinical man-
agement of patients suspected of CMI with focus on
occlusive arterial CMI.
Clinical presentation
CMI is deﬁned as insuﬃcient blood supply to the
gastrointestinal (GI) tract resulting in ischemic symp-
toms with duration of at least three months.1 Typical
symptoms of CMI include postprandial abdominal
pain with food aversion and weight loss. The abdom-
inal pain is classically located in the mid-abdomen or
epigastrium and starts usually 20–30minutes after a
meal with a duration of 1–2 hours. Atypical symptoms
are constant abdominal discomfort, nausea, vomiting,
diarrhea or constipation.1 Abdominal bruit may be pre-
sent during physical examination; however, the ‘‘classic
CMI triad’’ of postprandial abdominal pain, weight
loss and abdominal bruit is only present in 16–22%
of CMI patients.4,5
Etiology
Atherosclerotic stenosis of one or more mesenteric
arteries is the cause in >90% of CMI cases.6 Less fre-
quently CMI is caused by vasculitis. Three mesenteric
arteries provide blood supply to the intestines: the
celiac artery (CA), superior mesenteric artery (SMA)
and inferior mesenteric artery (IMA). An extensive col-
lateral circulation exists between these arteries.
Asymptomatic mesenteric stenoses are common in the
general population and prevalence increases with age.
The prevalence of asymptomatic CA and/or SMA sten-
osis is reported as 3% in patients under 65 years and
18% in patients older than 65 years.7
Multi-vessel mesenteric stenosis causing CMI is a
well-accepted conception, whereas insuﬃcient blood
supply caused by isolated mesenteric stenosis is thought
to be limited because of abundant collaterals. If the
collateral circulation is insuﬃcient, however, revascu-
larization of a single-vessel stenosis will result in symp-
tom relief.5,8–10
The most common cause of isolated CA stenosis is
median arcuate ligament syndrome (MALS): anatom-
ical eccentric compression of the CA and/or celiac gan-
glion by the median arcuate ligament (MAL) and
diaphragmatic crura.11 The degree of stenosis caused
by the MAL depends on the respiratory cycle. The
MAL moves caudally during inspiration, releasing the
compression on the CA and increasing compression
during expiration (Figure 1), although compression
only during inspiration may be observed as well.
Characteristics of patients with CMI diﬀer depending
upon the underlying cause being MALS or atheroscler-
osis (Table 1).12–18
Chronic non-occlusive ischemia (NOMI) or
‘‘migraine abdominale’’19 is characterized by symptoms
of CMI in the absence of a vascular stenosis and is
diagnosed in up to 13–16% of all CMI patients.10
Several pathophysiological mechanisms causing
chronic NOMI have been suggested: underlying condi-
tions such as cardiac and pulmonic insuﬃciency,
shunts, occlusion of smaller arteries due to spasms or
micro-emboli, and autonomic dysfunction. Therapy is
directed to ameliorate the adverse eﬀects of the under-
lying pathophysiological mechanism that is vasodilat-
ing medication in case of autonomic dysfunction or
optimizing oxygen supply to the GI tract in case of
underlying cardiac or pulmonic disease. Successful
treatment of these patients, however, is challenging
because the etiology of chronic NOMI is not fully unra-
veled yet.
Diagnosis
In the absence of a golden standard test, the diagnosis
of CMI is established by consensus in a multidisciplin-
ary meeting attended by vascular surgeons, gastroenter-
ologists and (interventional) radiologists.1,20 The
consensus diagnosis is based on clinical symptoms,
radiological evaluation of the mesenteric vasculature
and, if available, functional assessment of mucosal
ischemia.21–23 The value of symptoms alone is limited
for the prediction of the diagnosis of CMI.4,24,25
Computed tomography angiography (CTA) is the
primary imaging modality in patients with a moderate
or high suspicion of CMI to assess the mesenteric
arteries and to detect other intra-abdominal pathology
according to the ESVS guidelines.1 CTA depicts vari-
ous atherosclerotic plaque components such as soft
plaque and calciﬁcations with a sensitivity for mesen-
teric artery stenosis of 100% and a speciﬁcity of 95%.26
Current magnetic resonance angiography (MRA) tech-
niques seem not as accurate as CTA, especially for the
IMA and smaller branch vessels.27 When CTA is not
feasible, that is in the presence of contrast allergy or
renal insuﬃciency, MRA can be used as an alternative
according to the ACR guidelines.2 Duplex ultrasound
(DUS) can be used as ﬁrst screening imaging modality
to identify a mesenteric artery stenosis. DUS identiﬁes
a 70% CA stenosis with a sensitivity of 72–100% and
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a speciﬁcity of 77–90% and a 70% SMA stenosis with
a sensitivity of 72–100% and a speciﬁcity of 84–
98%.3,28 However, DUS is operator dependent, tech-
nically challenging and the ﬂow velocities of the evalu-
ated artery could be inﬂuenced by respiration, the
presence of concomitant stenosis in other mesenteric
vessels, and existing stents. Digital subtraction angiog-
raphy (DSA) is reserved for treatment of occlusive mes-
enteric artery disease and is replaced by CTA as
diagnostic modality. Plain abdominal X-ray has no
role in the diagnosis of CMI.
Dynamic imaging is important to detect a CA sten-
osis caused by MALS because the grade of stenosis
Figure 1. A 48-year-old woman presented with postprandial abdominal pain and 10-kg weight loss. Computed tomography angiography
(CTA) showed compression of the celiac artery (CA), with increased compression on expiration (a) and less compression on inspiration (b).
Patient was planned for surgical release of CA. After successful release, patient had gained 5 kg in weight and was symptom free. CTA 11
months after surgery showed an open CA on expiration (c) and on inpiration (d).
Table 1. Reported prevalence of characteristics of patients with
atherosclerotic CMI versus patients with CMI based on MALS.
Atherosclerotic CMI12 MALS13–18
Mean age (years) 69 37–54
Female 62% 69–78%
Smoking 66% 33–63%
Hypertension 64% 33%
Hyperlipidemia 41% 13%
CVD 54% 6%
CMI: chronic mesenteric ischemia; CVD: cardiovascular disease; MALS:
median arcuate ligament syndrome.
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varies with respiration in contrast to atherosclerotic
stenosis. CTA, MRA, DUS or DSA during both inspir-
ation and expiration phases are suﬃcient.
A functional test to prove actual GI ischemia is
needed because of the high prevalence of mesenteric
stenosis in the asymptomatic general population and
the large overlap of symptoms of CMI with many
other disorders. Visible light spectroscopy (VLS) per-
formed during upper endoscopy allows measuring of
the oxygen saturation of the upper GI mucosa using
a ﬁber-optic catheter passed through the accessory
channel of the endoscope connected to the VLS oxim-
eter (T-Stat 303 Microvascular Oximeter; Spectros,
Portola Valley, California).29 The sensitivity of VLS
measurements for the diagnosis of CMI is 90% and the
speciﬁcity is 60%.30 The VLS measurements are repro-
ducible in clinical practice with fair to good intraobserver
and interobsever reliability.31 Tonometry is another func-
tional test that measures luminal partial pressure of
carbon dioxide (PCO2) by a nasogastric and nasojejunal
catheter attached to a capnography (Tonocap). Luminal
PCO2 increases during mesenteric ischemia. Exercise
tonometry is performed during a bicycle test (sensitivity
78%, speciﬁcity 92%10) and 24-hour tonometry is per-
formed using test meals as provocation (sensitivity 76%,
speciﬁcity 94%23). A functional test is not needed in the
work-up of the most common CMI suspected patients
with typical symptoms and multi-vessel disease
(Figure 2). However, especially in the work-up of
single-vessel disease a functional test is a prerequisite. It
is therefore recommended to refer these patients to a
specialized center to undergo functional testing.
Research is in progress to develop simple and reliable
functional tests that can be widely applied.
Laboratory tests such as leukocytes, D-dimer, lac-
tate and C-reactive protein are not useful for detection
of CMI.1,32,33 Because CMI is a state of transient ische-
mia episodes induced by eating, fasted marker levels are
presumably not suﬃcient to indicate CMI. In a study in
which several serum markers before and after a meal
were determined in patients suspected of CMI, a sig-
niﬁcant increase of D-dimer was reported in 32 CMI
patients after a meal in contrast with 8 patients without
CMI.32 Another study in 49 CMI-suspected patients
reported a signiﬁcant increase in intestinal fatty acid–
binding protein levels in patients with a positive tono-
metry result after a meal in contrast with patients with a
normal response after a meal.33 Further research and
larger studies are needed to potentially identify a sensi-
tive and speciﬁc biomarker for detecting CMI.
In contrast to a diagnosis of acute ischemic colitis,
endoscopic assessment of the mucosa by visual appraisal
or taking biopsies plays no crucial role in detecting CMI.
In CMI patients atrophy of the duodenal mucosa and
non-Helicobacter pylori/non-nonsteroidal anti-inﬂam-
matory drug gastric or duodenal ulcers are observed in
a minority of cases.24 Histological examination of biopsy
samples are not discriminative for the diagnosis of
CMI.34 Nevertheless, an upper endoscopy remains indi-
cated in CMI-suspected patients to exclude alternative
diagnoses, such as peptic ulcer.
Multi-vessel stenoses and classic symptoms will lead
to a straightforward diagnosis of CMI. In case of
single-vessel disease careful investigation for alternative
causes is warranted.1 Exclusion of other etiologies by
imaging of the upper abdomen (DUS/computed tom-
ography (CT)/magnetic resonance (MR)) for gallstones
and pancreatitis and upper endoscopy in patients sus-
pected of CMI is important to prevent overtreatment
(Figure 2). When a consensus diagnosis of
occlusive CMI is established in the multidisciplinary
meeting, patients are planned for revascularization
therapy. A deﬁnitive diagnosis of CMI is proven
when technically successful treatment results in durable
symptom relief.
Therapy
Revascularization is indicated in patients with occlusive
CMI to relieve symptoms, improve quality of life,
restore normal weight and improve survival by prevent-
ing bowel infarction (acute-on-chronic mesenteric
ischemia).1 The challenge is to select the patient with
mesenteric stenosis who will beneﬁt from treatment.
Revascularization is accepted in case of symptomatic
multi-vessel stenosis (Figure 3). Because the presence
of the mesenteric collateral circulation is assumed to
prevent single-vessel CMI, revascularization is up for
discussion in case of single-vessel stenosis (Figure 1
and Figure 4). However, after careful selection by
multidisciplinary consensus and functional assessment
persistent symptom relief was reported in 73% of symp-
tomatic patients diagnosed with single-vessel CMI
based on a solitary CA or SMA stenosis.9
Open surgical revascularization has been the stand-
ard therapy modality for years. However, endovascular
revascularization is less invasive and has become the
therapy of choice in most centers over the past two
decades.1–3 The number of endovascular procedures
performed for CMI in the USA has increased signiﬁ-
cantly from 0.6 per million in 2000 to 4.5 per million in
2012 (p< 0.01).35
Prospective studies comparing percutaneous trans-
luminal angioplasty (PTA) alone with primary stenting
are lacking. However, in parallel to renal artery stenosis
and the advantage of stent placement over PTA in this
patient group, endovascular therapy for mesenteric
stenosis consists of stent placement according to the
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Patients suspected of CMI
Exclude other causes
-Imaging upper abdomen (DUS/CT/MR)
-Upper endoscopy
Mesenteric CTA to detect stenosis
If CTA is contra-indicated: MRA
No- stenosis
Symptoms not
typical for CMI
Symptoms
of CMI
Symptoms not
typical for CMI
Symptoms 
 of CMI
Symptoms not  
typical for CMI
Symptoms  
 of CMI
Functional
test*
No CMI
Therapy for underlying
condition
vasodilating medication
MALS:
endoscopic retroperitoneal
release
NOMI No CMI No CMICMI
Atherosclerosis: PMAS
Atherosclerosis: PMAS
CMI
Multidisciplinary meeting for
consensus diagnosis
Multidisciplinary meeting for
consensus diagnosis
Multidisciplinary meeting for
consensus diagnosis
Functional
test*
Functional
test*
Isolated CA or SMA stenosis Multi-vessel stenosis
Figure 2. Algorithm for clinical management of chronic mesenteric ischemia.
*Refer for functional test. Suitable functional tests are upper gastrointestinal endoscopy with visible light spectroscopy or gastric-jejunal
tonometry (24-hour tonometry or exercise tonometry).
CA: celiac artery; CMI: chronic mesenteric ischemia; CT: computed tomography; CTA: computed tomography angiography; DUS: duplex
ultrasound; MR: magnetic resonance; MRA: magnetic resonance angiography; MALS: median arcuate ligament syndrome; NOMI: non-
occlusive mesenteric ischemia; PMAS: percutaneous mesenteric artery stenting; SMA: superior mesenteric artery.
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Figure 3. A 69-year-old woman presented with postprandial abdominal pain and 10-kg weight loss over three months. A significant
stenosis of the celiac artery (CA) and superior mesenteric artery (SMA) was shown on computed tomography angiography (CTA) (a). A
consensus diagnosis of multi-vessel chronic mesenteric ischemia was established and patient was planned for endovascular revascu-
larization. The CA and SMA were successfully stented. CTA 6 months after revascularization showed open stents (b). The patient was free
of symptoms and her weight increased by 12 kg.
Figure 4. A 50-year-old man presented with postprandial abdominal pain and 13-kg weight loss. Computed tomography angiography
(CTA) showed a significant stenosis of the superior mesenteric artery (SMA) and <50% celiac artery stenosis (a). His mucosal saturation
levels were decreased as detected by visible light spectroscopy. A consensus diagnosis of single-vessel chronic mesenteric ischemia was
established and patient was planned for stent placement of the SMA. CTA 6 months after revascularization showed an open SMA stent (b).
The patient was free of symptoms and his weight increased by 7 kg.
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ESVS and SIR guidelines.1,3 Mesenteric stenoses are
usually located at the ostium and are therefore prone
to recoil after PTA.3,36,37 The endovascular approach is
transbrachial or transfemoral, but a transradial
approach for percutaneous mesenteric artery stenting
(PMAS) is recognized as a safe alternative to the trans-
brachial approach.38 Bare-metal stents are standard
care but retrospective data have reported better pri-
mary patency rates when using covered stents.39
Outcome of a Dutch randomized multicenter clinical
trial (NCT02428582) is currently awaited to conﬁrm
the superiority of covered stents for PMAS.
Open surgical revascularization can be considered if
endovascular approach has failed, if endovascular
revascularization is technically not possible due to
extensive occlusion and calciﬁcation and contraindica-
tions to radiation or contrast media, or if revascular-
ization is needed in young patients with complex
non-atherosclerotic lesions caused by vasculitis or
mid-aortic syndrome.1 Open surgical revascularization
can be performed antegrade (from the supraceliac
aorta), or retrograde (from the iliac artery), or hybrid
with open access to the SMA and retrograde stenting.
Autogenously revascularization techniques are ﬁrst
choice but a prosthetic conduit can be used as bypass
for one or more vessels as well.
Overall technical success rates of endovascular mes-
enteric revascularization varied from 85–100% versus
technical success rates of surgical revascularization of
97–100%.3,6,40 Relative contraindications for endovas-
cular revascularization associated with lower technical
success rate and/or increased procedural complications
are highly tortuous aorta-iliac arteries, long-segment
occlusion, small-diameter distal vessels and heavily cal-
ciﬁed stenosis.3 It should be emphasized that ostial
occlusion does not exclude PMAS. In a study of 185
CA and SMA vessels treated with PMAS, 21% of the
revascularized vessels (9 CA and 30 SMA) were
occluded prior to PMAS.41
Complication rates of surgical revascularization in
CMI patients are reported as 13–40%24,42 and endovas-
cular complication rates has been reported between 0
and 31% (Table 2).2,3 In 4–38% of the cases the com-
plication of the endovascular intervention is access site
related, whereby access site hematomas are most
reported.3,12
The therapy for MALS consists of surgical release of
the MAL, adjacent crus of the diaphragm and removal
of the celiac plexus (Figure 4). If stenosis of the CA
persists after adequate surgical release, additional
bypass surgery or endovascular therapy is performed.43
An endoscopic retroperitoneal release is favorable
because this has proved feasible and less invasive with
comparable short-term results with the open proced-
ure.17 PMAS is contraindicated as primary therapy
for MALS, because of the high risk of stent fracture
resulting in restenosis.3
Clinical outcome after treatment
Repeated follow-up after therapy for CMI might be
considered to detect symptomatic restenosis according
to the ESVS guidelines.1 Routine repeated imaging
after therapy may show restenosis, but the beneﬁt of
treating asymptomatic restenosis is unknown.
Antiplatelet therapy is recommended after revasculari-
zation and dual antiplatelet therapy may be considered
for 3–12 months.1–3
In-stent stenosis can be seen in 28–36% of endovas-
cular-treated patients within 2 years after PMAS.3 This
number is lower after surgical revascularization with 0–
25%.6,40 Independent predictors of restenosis after mes-
enteric revascularization are endovascular revasculari-
zation, prior mesenteric intervention, female gender
and small (<6mm) SMA diameter.44 Severe mesenteric
calciﬁcation, occlusions, longer lesions and small vessel
diameter are associated with an increased risk of distal
embolization, restenosis and reinterventions after endo-
vascular revascularization.40
Surgical revascularization is associated with a super-
ior long-term patency rate compared to endovascular
revascularization (cumulative odds ratio 3.57, 95%
conﬁdence interval (CI) 1.82–6.87, p¼ 0.0002).45
Table 3 shows the 1-year and 5-year primary patency
rates and primary assisted patency rates of surgical
versus endovascular revascularization.3,41,45,46
A recently published meta-analysis included 100
observational studies to compare endovascular revascu-
larization (10,679 patients) and open surgical revascu-
larization (8047 patients).12 Risk of in-hospital
complications was signiﬁcantly increased in the open
surgical revascularization group (relative risk (RR)
2.19, 95% CI 1.84–2.60). The risk of 3-year recurrence
was lower in the patients treated with open surgery than
Table 2. Reported type of complications of mesenteric endovas-
cular revascularization versus mesenteric surgical
revascularization.
Complications of endovascular
revascularization2,3
Complications of surgical
revascularization24,42
Hematoma Bowel resection
Access site dissection Acute renal failure
Mesenteric dissection Acute myocardial infarction
Thrombosis Stroke
Branch perforation Peripheral vascular disease
Stent dislodgement Hemorrhage
Distal thromboembolization Respiratory failure
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in the patients treated with endovascular approach
(RR 0.47, 95% CI 0.34–0.66). The 3-year survival
rate was not signiﬁcantly diﬀerent (RR 0.96, 95% CI
0.86–1.07). The ESVS guidelines recommend to oﬀset
the superior long-term results of open revascularization
against the possible early beneﬁts of endovascular
revascularization in the absence of randomized con-
trolled trials.1
Immediate symptom relief is reported in 90–98% of
surgical-treated patients and remains excellent after 5
years with 89–92%.6 After endovascular revasculariza-
tion, immediate symptom relief was reported in 87–
95%, symptom relief after 3 years in 61–88%, and in
51% after 5 years.6
A retrospective analysis of prospectively collected
data (10,920 endovascular revascularized patients
versus 4555 surgical revascularized patients) showed
that endovascular revascularization is associated with
a signiﬁcantly lower in-hospital mortality rate of 2.4%,
shorter length of hospitalization by 10 days, and lower
costs of hospitalization with a saving of $25,000 com-
pared to surgical revascularization.47
Conclusion
This review provides an overview on the current clinical
management of CMI, which is summarized in an algo-
rithm (Figure 2). Although the exact incidence of CMI
is unknown, it is expected that the incidence will
increase in the upcoming years due to the aging popu-
lation and the increasing prevalence of cardiovascular
disease in Europe. Cardiovascular disease patients have
an increased life expectancy due to the improved diag-
nostics and better therapeutic opportunities, but these
patients are also prone to develop mesenteric athero-
sclerosis. Patients with CMI present usually with GI
symptoms. The diagnostic work-up of the patient sus-
pected of CMI and therapeutic management is multi-
disciplinary. Early diagnosis is important to timely
treat, improve quality of life and to prevent acute-on-
chronic mesenteric ischemia.
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